SPV106

SPV106 has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Sep 18, 2025: “Reversion of aortic valve cells calcification by activation of Notch signalling via histone acetylation induction”.

Intervention

1 paper studies it4 findingsUpdated

PubChem

See all 1 papers on SPV106

At a glance

The findings reach mice, none yet in people. 1 lab in 2 countries.

None of its findings points the other way.

Cells and mice: a single group. Worms or flies and humans: nothing yet.
  • 1 lab in 2 countries
  • Animals1

What did studies of SPV106 find?

4

Studies of SPV106 measured 4 outcomes, among them cardiac function, calcification of the aortic valve and calcific lesions.

Cardiac function

upin mice1

1 study
  1. SPV106 improves cardiac function in Vitamin-D-induced calcification model.

    “positively preserved the valve motion compromised by calcification and the overall cardiac function.”

    Animalsin Vitamin-D-induced calcification model

    Reversion of aortic valve cells calcification by activation of Notch signalling via histone acetylation induction

    Signal transduction and targeted therapy

Calcification of the aortic valve

downin mice1

1 study
  1. SPV106 decreases calcification of the aortic valve in Vitamin-D-induced calcification model.

    “In vivo treatment with SPV106 reduced calcification of the valve induced by administering Vitamin-D”

    Animalsin Vitamin-D-induced calcification model

    Reversion of aortic valve cells calcification by activation of Notch signalling via histone acetylation induction

    Signal transduction and targeted therapy

More on Calcification of the aortic valve

Calcific lesions

downin human cells1

1 study
  1. SPV106 prevents calcific lesions in human cells (ex vivo model of aortic valve calcification).

    “The treatment also prevented the accumulation of calcific lesions in an ex vivo model of aortic valve calcification.”

    Cellsex vivo model of aortic valve calcification

    Reversion of aortic valve cells calcification by activation of Notch signalling via histone acetylation induction

    Signal transduction and targeted therapy

NOTCH1

upin human cells1

1 study
  1. SPV106 increases NOTCH1 in cultured human VICs.

    “In human VICs, SPV106 restored Histone acetylation marks, modified general chromatin accessibility and upregulated expression of Notch1”

    Cellsin cultured human VICs

    Reversion of aortic valve cells calcification by activation of Notch signalling via histone acetylation induction

    Signal transduction and targeted therapy

More on NOTCH1

Latest